keyword
https://read.qxmd.com/read/38535893/effects-of-quercetin-on-the-dna-methylation-pattern-in-tumor-therapy-an-updated-review
#1
REVIEW
Qin Wang, Chen Ma, Nan Wang, Huixian Mao
Quercetin is a unique bioactive flavonoid, and is an excellent antioxidant and has anti-tumor effects by regulating different tumor-related processes like proliferation, apoptosis, invasion, and spread. The latest investigations reveal that quercetin may have the capability to influence DNA methylation modification, one of the primary factors in the development of tumors. Despite the fact that quercetin has significant therapeutic properties, its use as an anti-tumor medicine is constrained by its poor solubility, short half-life, and ineffective tumor targeting...
March 27, 2024: Food & Function
https://read.qxmd.com/read/38534575/disulfide-cross-linked-polymeric-redox-responsive-nanocarrier-based-on-heparin-chitosan-and-lipoic-acid-improved-drug-accumulation-increased-cytotoxicity-and-selectivity-to-leukemia-cells-by-tumor-targeting-via-aikido-principle
#2
JOURNAL ARTICLE
Igor D Zlotnikov, Alexander A Ezhov, Natalia V Dobryakova, Elena V Kudryashova
We have developed a micellar formulation of anticancer drugs based on chitosan and heparin grafted with lipoic and oleic acids that can release the cytotoxic cargo (doxorubicin) in response to external stimuli, such as increased glutathione concentration-a hallmark of cancer. Natural polysaccharides (heparin and chitosan) provide the pH sensitivity of the nanocarrier: the release of doxorubicin (Dox) is enhanced in a slightly acidic environment (tumor microenvironment). Fatty acid residues are necessary for the formation of nanoparticles (micelles) and solubilization of cytostatics in a hydrophobic core...
February 20, 2024: Gels
https://read.qxmd.com/read/38533911/the-role-of-cxcl11-and-its-receptors-in-cancer-prospective-but-challenging-clinical-targets
#3
REVIEW
Jiaqi Wang, Xinting Ouyang, Weijian Zhu, Qiang Yi, Jinghua Zhong
Chemokine ligand 11 is a member of the CXC chemokine family and exerts its biological function mainly through binding to CXCR3 and CXCR7. The CXCL11 gene is ubiquitously overexpressed in various human malignant tumors; however, its specific mechanisms vary among different cancer types. Recent studies have found that CXCL11 is involved in the activation of multiple oncogenic signaling pathways and is closely related to tumorigenesis, progression, chemotherapy tolerance, immunotherapy efficacy, and poor prognosis...
2024: Cancer Control: Journal of the Moffitt Cancer Center
https://read.qxmd.com/read/38533261/potential-pharmacological-mechanisms-of-tanshinone-iia-in-the-treatment-of-human-neuroblastoma-based-on-network-pharmacological-and-molecular-docking-technology
#4
JOURNAL ARTICLE
Ning Tang, Yan Wang, Jiarui Miao, Yang Zhao, Yue Cao, Wentao Sun, Jingke Zhang, Hua Sui, Bing Li
Tanshinone IIA (Tan-IIA) is the main bioactive component of Chinese herbal medicine salvia miltiorrhiza (Danshen). Sodium sulfonate of Tan-IIA is widely used in the treatment of cardiovascular and cerebrovascular diseases. Tan-IIA also has inhibitory effects on tumor cells such as gastric cancer, but its therapeutic effect and mechanism on human neuroblastoma have not been evaluated, so its pharmacological mechanism is systematically evaluated by the combined method of network pharmacology and molecular docking...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38532108/co-targeting-cd47-and-vegf-elicited-potent-anti-tumor-effects-in-gastric-cancer
#5
JOURNAL ARTICLE
Kaiqi Zhang, Yuan Xu, Xusheng Chang, Caili Xu, Wenjing Xue, Dan Ding, Mingming Nie, Hui Cai, Jun Xu, Lu Zhan, Jiangbo Han, Tiancai Cai, Dianwen Ju, Li Feng, Xuyao Zhang, Kai Yin
BACKGROUND: CD47, serving as an intrinsic immune checkpoint, has demonstrated efficacy as an anti-tumor target in hematologic malignancies. Nevertheless, the clinical relevance of CD47 in gastric cancer and its potential as a therapeutic target remains unclear. METHODS: The expression of CD47 in clinical gastric cancer tissues was assessed using immunohistochemistry and Western blot. Patient-derived cells were obtained from gastric cancer tissues and co-cultured with macrophages derived from human peripheral blood mononuclear cells...
March 27, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38530846/a-phase-i-trial-of-nab-paclitaxel-bevacizumab-ab160-nano-immunoconjugate-therapy-for-gynecologic-malignancies
#6
JOURNAL ARTICLE
Eleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, Vera J Suman, Jill M Schimke, Carrie A Strand, Lisa A Kottschade, Rachel A Kudgus, Sarah A Buhrow, Laura R Becher, Liyi Geng, Gretchen E Glaser, Megan E Grudem, Aminah Jatoi, Carolyn M Klampe, Amanika Kumar, Carrie L Langstraat, Robert R McWilliams, Andrea E Wahner Hendrickson, S John Weroha, Yiyi Yan, Joel M Reid, Svetomir N Markovic, Matthew S Block
PURPOSE: AB160 is a 160 nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles non-covalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that AB160 resulted in greater tumor targeting and tumor inhibition compared to sequential treatment with ABX then BEV. Given individual drug activity, we investigated the safety and toxicity of AB160 in patients with gynecologic cancers. PATIENTS AND METHODS: A 3+3 phase I trial was conducted with 3 potential dose levels in patients with previously treated endometrial (EC), cervical (CC), and platinum-resistant ovarian cancer (OC) patients to ascertain the recommended Phase II dose (RP2D)...
March 26, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38528632/harnessing-adenovirus-in-cancer-immunotherapy-evoking-cellular-immunity-and-targeting-delivery-in-cell-specific-manner
#7
REVIEW
Miao Zeng, Wei Zhang, Yisheng Li, Li Yu
Recombinant adenovirus (rAd) regimens, including replication-competent oncolytic adenovirus (OAV) and replication-deficient adenovirus, have been identified as potential cancer therapeutics. OAV presents advantages such as selective replication, oncolytic efficacy, and tumor microenvironment (TME) remodeling. In this perspective, the principles and advancements in developing OAV toolkits are reviewed. The burgeoning rAd may dictate efficacy of conventional cancer therapies as well as cancer immunotherapies, including cancer vaccines, synergy with adoptive cell therapy (ACT), and TME reshaping...
March 25, 2024: Biomarker Research
https://read.qxmd.com/read/38526801/reduction-sensitive-polymeric-carrier-for-the-targeted-delivery-of-a-quinazoline-derivative-for-enhanced-generation-of-reactive-oxygen-species-against-cancer
#8
JOURNAL ARTICLE
Jianrong Cao, Keze Hong, Chengqi Lv, Weiting Jiang, Qi Chen, Rongze Wang, Yong Wang
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors and the development of effective therapeutics against HCC is urgently needed. A novel quinazoline derivative 04NB-03 (Qd04) has been proved to be highly effective against HCC without obvious toxic side-effects. However, the poor water solubility and low bioavailability in vivo severely limit its clinical application. In addition, Qd04 kills tumor cells by inducing an accumulation of endogenous reactive oxygen species (ROS), which is highly impeded by the overexpression of glutathione (GSH) in tumor cells...
March 25, 2024: Biomaterials Science
https://read.qxmd.com/read/38526322/albumin-ruthenium-catalyst-conjugate-for-bio-orthogonal-uncaging-of-alloc-group
#9
JOURNAL ARTICLE
Kimberly S Taylor, Madison M McMonagle, Schaelee C Guy, Ariana M Human-McKinnon, Shumpei Asamizu, Heidi J Fletcher, Bradley W Davis, Takashi L Suyama
The employment of antibodies as a targeted drug delivery vehicle has proven successful which is exemplified by the emergence of antibody-drug conjugates (ADCs). However, ADCs are not without their shortcomings. Improvements may be made to the ADC platform by decoupling the cytotoxic drug from the delivery vehicle and conjugating an organometallic catalyst in its place. The resulting protein-metal catalyst conjugate was designed to uncage the masked cytotoxin administered as a separate entity. Macropinocytosis of albumin by cancerous cells suggests the potential of albumin acting as the tumor-targeting delivery vehicle...
March 25, 2024: Organic & Biomolecular Chemistry
https://read.qxmd.com/read/38525011/targeted-ultrasound-nanobubbles-therapy-for-prostate-cancer-via-immuno-sonodynamic-effect
#10
JOURNAL ARTICLE
Xin Huang, Yueying Chen, Fanglu Zhong, Bin Gui, Yugang Hu, Yuxin Guo, Qing Deng, Qing Zhou
BACKGROUND: Prostate cancer (PCa) poses a significant global health threaten. Immunotherapy has emerged as a novel strategy to augment the inhibition of tumor proliferation. However, the sole use of anti-PD-L1 Ab for PCa has not yielded improvements, mirroring outcomes observed in other tumor types. METHODS: This study employed the thin film hydration method to develop lipid nanobubbles (NBs) encapsulating chlorin e6 (Ce6) and anti-PD-L1 Ab (Ce6@aPD-L1 NBs). Our experimental approach included cellular assays and mouse immunization, providing a comprehensive evaluation of Ce6@aPD-L1 NBs' impact...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38522159/tumor-microenvironment-activated-mussel-inspired-hollow-mesoporous-nanotheranostic-for-enhanced-synergistic-photodynamic-chemodynamic-therapy
#11
JOURNAL ARTICLE
Hao Tian Yan, Moon-Sun Jang, Changling Liu, Qiang Fu, Bo Wang, Yan Fu, Jung Hee Lee, Hong Yu Yang
Anti-tumor therapies reliant on reactive oxygen species (ROS) as primary therapeutic agents face challenges due to a limited oxygen substrate. Photodynamic therapy (PDT) is particularly hindered by inherent hypoxia, while chemodynamic therapy (CDT) encounters obstacles from insufficient endogenous hydrogen peroxide (H2 O2 ) levels. In this study, we engineered biodegradable tumor microenvironment (TME)-activated hollow mesoporous MnO2 -based nanotheranostic agents, designated as HAMnO2 A. This construct entails loading artemisinin (ART) into the cavity and surface modification with a mussel-inspired polymer ligand, namely hyaluronic acid-linked poly(ethylene glycol)-diethylenetriamine-conjugated (3,4-dihydroxyphenyl) acetic acid, and the photosensitizer Chlorin e6 (mPEG-HA-Dien-(Dhpa/Ce6)), facilitating dual-modal imaging-guided PDT/CDT synergistic therapy...
March 23, 2024: Journal of Colloid and Interface Science
https://read.qxmd.com/read/38521987/a-t-cell-inspired-sonoporation-system-enhances-low-dose-x-ray-mediated-pyroptosis-and-radioimmunotherapy-efficacy-by-restoring-gasdermin-e-expression
#12
JOURNAL ARTICLE
Hao Yin, Xiaoqu Hu, Congying Xie, Yida Li, Yanjun Gao, Hanqian Zeng, Wenting Zhu, Danli Xie, Qinyang Wang
Genome editing has the potential to improve the unsatisfactory therapeutic effect of antitumour immunotherapy. However, the cell plasma membrane prevents the entry of almost all free genome-manipulation agents (e.g., DNAs, RNAs, proteins). Therefore, a system that can be spatiotemporally controlled and can instantly open the cellular membrane to allow the entry of genome-editing agents into target cells is needed. Here, inspired by the ability of cytotoxic T cells to deliver cytotoxins to cancer cells by perforation, we established an easy-to-prepare and long shelf-stable ultrasound (US)-controlled perforation system (UPS) to enhance the delivery of free genome-manipulating agents...
March 24, 2024: Advanced Materials
https://read.qxmd.com/read/38520717/design-of-pd-l1-targeted-lipid-nanoparticles-to-turn-on-pten-for-efficient-cancer-therapy
#13
JOURNAL ARTICLE
Yelee Kim, Jiwoong Choi, Eun Hye Kim, Wonbeom Park, Hochung Jang, Yeongji Jang, Sung-Gil Chi, Dae-Hyuk Kweon, Kyuri Lee, Sun Hwa Kim, Yoosoo Yang
Lipid nanoparticles (LNPs) exhibit remarkable mRNA delivery efficiency, yet their majority accumulate in the liver or spleen after injection. Tissue-specific mRNA delivery can be achieved through modulating LNP properties, such as tuning PEGylation or varying lipid components systematically. In this paper, a streamlined method is used for incorporating tumor-targeting peptides into the LNPs; the programmed death ligand 1 (PD-L1) binding peptides are conjugated to PEGylated lipids via a copper-free click reaction, and directly incorporated into the LNP composition (Pep LNPs)...
March 23, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38517973/iterative-nanoparticle-bioengineering-enabled-by-x-ray-fluorescence-imaging
#14
JOURNAL ARTICLE
Giovanni M Saladino, Bertha Brodin, Ronak Kakadiya, Muhammet S Toprak, Hans M Hertz
Nanoparticles (NPs) are currently developed for drug delivery and molecular imaging. However, they often get intercepted before reaching their target, leading to low targeting efficacy and signal-to-noise ratio. They tend to accumulate in organs like lungs, liver, kidneys, and spleen. The remedy is to iteratively engineer NP surface properties and administration strategies, presently a time-consuming process that includes organ dissection at different time points. To improve this, we propose a rapid iterative approach using whole-animal x-ray fluorescence (XRF) imaging to systematically evaluate NP distribution in vivo...
March 22, 2024: Science Advances
https://read.qxmd.com/read/38517946/correction-to-rational-design-of-bioorthogonally-activatable-protac-for-tumor-targeted-protein-degradation
#15
Tao Bi, Pan Liang, Yanan Zhou, Hong Wang, Rui Huang, Qin Sun, Hongping Shen, Sijin Yang, Wei Ren, Zengjin Liu
No abstract text is available yet for this article.
March 22, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/38516170/mri-guided-cell-membrane-camouflaged-bimetallic-coordination-nanoplatform-for-combined-tumor-phototherapy
#16
JOURNAL ARTICLE
Mengyang Zhou, Yifei Wang, Yaning Xia, Yinhua Li, Jianfeng Bao, Yong Zhang, Jingliang Cheng, Yupeng Shi
Nanotechnology for tumor diagnosis and optical therapy has attracted widespread interest due to its low toxicity and convenience but is severely limited due to uncontrollable tumor targeting. In this work, homologous cancer cell membrane-camouflaged multifunctional hybrid metal coordination nanoparticles (DRu/Gd@CM) were prepared for MRI-guided photodynamic therapy (PDT) and photothermal therapy (PTT) of tumors. Bimetallic coordination nanoparticles are composed of three functional modules: dopamine, Ru(dcbpy)3 Cl2 and GdCl3 , which are connected through 1,4-Bis[(1H-imidazole-1-yl)methyl]benzene (BIX)...
June 2024: Materials today. Bio
https://read.qxmd.com/read/38514970/acidity-triggered-sticky-spotlight-cck2r-targeted-tme-sensitive-nir-fluorescent-probes-for-tumor-imaging-in-vivo
#17
JOURNAL ARTICLE
Ruiqi Sun, Yuxin Wang, Wenhui Shi, Hongfu Zhang, Jianhua Liu, Weina He
Cancer which causes high mortality globally threatens public health seriously. There is an urgent need to develop tumor-specific near-infrared (NIR) imaging agents to achieve precise diagnosis and guide effective treatment. In recent years, imaging probes that respond to acidic environments such as endosomes, lysosomes, or acidic tumor microenvironments (TMEs) are being developed. However, because of their nonspecific internalization by both normal and tumor cells, resulting in a poor signal-to-noise ratio in diagnosis, these pH-sensitive probes fail to be applied to in vivo tumor imaging...
March 21, 2024: Bioconjugate Chemistry
https://read.qxmd.com/read/38514793/early-induction-of-cytokine-release-syndrome-by-rapidly-generated-car-t-cells-in-preclinical-models
#18
JOURNAL ARTICLE
Arezoo Jamali, Naphang Ho, Angela Braun, Elham Adabi, Frederic B Thalheimer, Christian J Buchholz
Cytokine release syndrome (CRS) is a significant side-effect of conventional chimeric antigen receptor (CAR) T-cell therapy. To facilitate patient accessibility, short-term (st) CAR T cells, which are administered to patients only 24 h after vector exposure, are in focus of current investigations. Their impact on the incidence and severity of CRS has been poorly explored. Here, we evaluated CD19-specific stCAR T cells in preclinical models. In co-culture with tumor cells and monocytes, stCAR T cells exhibited anti-tumoral activity and potent release of CRS-related cytokines (IL-6, IFN-γ, TNF-α, GM-CSF, IL-2, IL-10)...
March 21, 2024: EMBO Molecular Medicine
https://read.qxmd.com/read/38514660/tertiary-lymphoid-structures-and-b-cells-determine-clinically-relevant-t-cell-phenotypes-in-ovarian-cancer
#19
JOURNAL ARTICLE
Lenka Kasikova, Jana Rakova, Michal Hensler, Tereza Lanickova, Jana Tomankova, Josef Pasulka, Jana Drozenova, Katerina Mojzisova, Anna Fialova, Sarka Vosahlikova, Jan Laco, Ales Ryska, Pavel Dundr, Roman Kocian, Tomas Brtnicky, Petr Skapa, Linda Capkova, Marek Kovar, Jan Prochazka, Ivan Praznovec, Vladimir Koblizek, Alice Taskova, Hisashi Tanaka, Robert Lischke, Fernando Casas Mendez, Jiri Vachtenheim, Viola Heinzelmann-Schwarz, Francis Jacob, Iain A McNeish, Michal J Halaska, Lukas Rob, David Cibula, Sandra Orsulic, Lorenzo Galluzzi, Radek Spisek, Jitka Fucikova
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) are associated with an increased intratumoral density of CD8+ effector T (TEFF ) cells and TIM3+ PD1+ , hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8+ T cells...
March 21, 2024: Nature Communications
https://read.qxmd.com/read/38513728/spatiotemporally-controlled-hydrophobic-drug-delivery-via-photosensitizer-driven-assembly-disassembly-for-enhanced-triple-negative-breast-cancer-treatment
#20
JOURNAL ARTICLE
Fanhui Kong, Peiying He, Jiani Jiang, Wei Zhu, Qi Lei
Therapeutic approaches for triple-negative breast cancer (TNBC) have been continuously advancing, but inadequate control over release behavior, insufficient tumor selectivity, and limited drug availability continue to impede therapeutic outcomes in nanodrug systems. In this study, we propose a general hydrophobic antineoplastic delivery system, termed spatiotemporally-controlled hydrophobic antineoplastic delivery system (SCHADS) for enhanced TNBC treatment. The key feature of SCHADS is the formation of metastable photosensitive-antineoplastic complexes (PACs) through the self-assembly of hydrophobic drugs driven by photosensitive molecules...
March 19, 2024: Journal of Controlled Release
keyword
keyword
90191
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.